Minor
LoCaMoTE-PD · Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
Trial sites expanded: 5 → 8 locations
Hillhurst Biopharmaceuticals, Inc.Phase 2 NCT07005180 Registry history of NCT07005180 on ClinicalTrials.gov (opens the registry)